Lucie Raskin: Comparing VTE Risk in Hormonal Contraceptives at NTHC 2026
Lucie Raskin, PhD student at University of Namur, shared on LinkedIn:
”Glad to have presented at NTHC 2026 (Namur Thrombosis and Hemostasis Center)!
I had the opportunity to share our work on a Network Meta-Analysis (NMA) assessing the risk of venous thromboembolism (VTE) associated with hormonal contraceptives (HCs).
This analysis allows us, within a single model, to compare the full range of HCs and to classify VTE risk according to the type of contraceptive.
By integrating all available evidence, this work provides a comprehensive overview that complements biological data and real-world pharmacovigilance findings.
Altogether, the evidence consistently suggests that natural estrogens may represent a safer option compared to EE-based COCs with respect to VTE risk.
I would like to thank my supervisors Jonathan Douxfils and Charlotte Beaudart, as well as the Research Unit in Clinical Pharmacology and Toxicology (URPC) team for their support.”
Stay updated with Hemostasis Today.
-
May 7, 2026, 17:56The Latest Clinical Data Shaping The Evolving Landscape of Hemophilia Treatment – EAHAD
-
May 7, 2026, 17:31Talha Badar: New Classical Hematology Chapter on Bleeding and Thrombosis
-
May 7, 2026, 17:26Maria Τektonidou: Gene Network Analysis Identifies STAT1 in Thrombotic APS
-
May 7, 2026, 17:23Sonu Bhaskar: Inflammatory Biomarkers in Acute Cerebral Venous Sinus Thrombosis
-
May 7, 2026, 16:53Patricio S. Espinosa: Anticoagulation Is Not an Absolute Contraindication to Amyloid Therapy
-
May 7, 2026, 16:34Arun V J: Give Blood and Be the Hero You Always Wanted to Be
-
May 7, 2026, 16:15August Bones: When Would You Consider Placing an Inferior Vena Cava Filter After a Pulmonary Embolism?
-
May 7, 2026, 15:58Stop Asking Doctors to Do More – Reimagining the Care Team – The US Oncology
-
May 7, 2026, 15:42Chokri Ben Lamine: CVC-Associated UE-DVT and Catheter Removal